Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;176(4):949-954.
doi: 10.1111/bjd.15077. Epub 2017 Mar 1.

Skin biopsy utilization and melanoma incidence among Medicare beneficiaries

M A Weinstock  1   2   3 , J P Lott  4 , Q Wang  5 , L J Titus  6   7 , T Onega  6   7   8 , H D Nelson  9   10 , L Pearson  5 , M Piepkorn  11   12 , R L Barnhill  13 , J G Elmore  14 , A N A Tosteson  5   6   15
Affiliations

Skin biopsy utilization and melanoma incidence among Medicare beneficiaries

M A Weinstock et al. Br J Dermatol. 2017 Apr.

Abstract

Background: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis.

Objectives: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports.

Methods: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002-2009.

Results: The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1-6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7-9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern.

Conclusions: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Lott is an employee of Bayer HealthCare Pharmaceuticals, LLC, which had no involvement in this research.

Figures

Figure 1
Figure 1
Association between Melanoma Incidence and Skin Biopsy Rates, Aggregated Across SEER States, 2002–2009
Figure 2
Figure 2
Associations between Melanoma Incidence and Skin Biopsy Rates, Stratified by SEER State, 2002–2009
See this image and copyright information in PMC

Comment in

References

    1. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481. - PMC - PubMed
    1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–613. - PubMed
    1. Ahn HS, Welch HG. South Korea's Thyroid-Cancer "Epidemic"--Turning the Tide. N Engl J Med. 2015;373(24):2389–2390. - PubMed
    1. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234–e242. - PMC - PubMed
    1. Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988–2006. J Invest Dermatol. 2010;130(3):793–797. - PubMed